Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-dose versus two-dose ivermectin mass drug administration for scabies and tungiasis in Southwest Ethiopia
PACTR202401655267670Phase 4Recruiting
- Sponsor
- Arba Minch University
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivermectin in scabies and tungiasis (2 arms), sponsored by Arba Minch University. Primary endpoint: Prevalence of scabies. Started Nov 2023; status: recruiting.
02
Drugs
ivermectin
03
Conditions
scabiestungiasis
Beyond the preview
Go deeper on PACTR202401655267670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202401655267670.